- Home
- OPAD vs BOLD Comparison
OPAD vs BOLD Comparison
Compare OPAD & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPAD
- BOLD
- Stock Information
- Founded
- OPAD 2015
- BOLD 2018
- Country
- OPAD United States
- BOLD United States
- Employees
- OPAD N/A
- BOLD N/A
- Industry
- OPAD Real Estate
- BOLD
- Sector
- OPAD Finance
- BOLD
- Exchange
- OPAD Nasdaq
- BOLD Nasdaq
- Market Cap
- OPAD 25.3M
- BOLD 24.4M
- IPO Year
- OPAD N/A
- BOLD 2024
- Fundamental
- Price
- OPAD $1.39
- BOLD $1.17
- Analyst Decision
- OPAD Hold
- BOLD Buy
- Analyst Count
- OPAD 5
- BOLD 3
- Target Price
- OPAD $2.38
- BOLD $4.00
- AVG Volume (30 Days)
- OPAD 142.8K
- BOLD 286.6K
- Earning Date
- OPAD 08-04-2025
- BOLD 08-11-2025
- Dividend Yield
- OPAD N/A
- BOLD N/A
- EPS Growth
- OPAD N/A
- BOLD N/A
- EPS
- OPAD N/A
- BOLD N/A
- Revenue
- OPAD $794,159,000.00
- BOLD N/A
- Revenue This Year
- OPAD N/A
- BOLD N/A
- Revenue Next Year
- OPAD $40.79
- BOLD N/A
- P/E Ratio
- OPAD N/A
- BOLD N/A
- Revenue Growth
- OPAD N/A
- BOLD N/A
- 52 Week Low
- OPAD $0.91
- BOLD $1.00
- 52 Week High
- OPAD $5.13
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- OPAD 70.23
- BOLD N/A
- Support Level
- OPAD $0.91
- BOLD N/A
- Resistance Level
- OPAD $1.59
- BOLD N/A
- Average True Range (ATR)
- OPAD 0.13
- BOLD 0.00
- MACD
- OPAD 0.06
- BOLD 0.00
- Stochastic Oscillator
- OPAD 77.94
- BOLD 0.00
About OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.